The long-term investor command center. One ticker, the whole case — a Quality / Value / Momentum / Smart-Money read on top of valuation-in-context, ROIC & moat, dividend health, trend, financial health, and who’s buying. Built only from SEC filings and end-of-day prices. Glass-box, no invented numbers.
Building ONCO’s long-term case…
Pulling SEC filings
Parsing XBRL fundamentals
Scoring quality, value & momentum
Checking who’s buying
Rendering
ONCO
Onconetix, Inc.Small cap · $1.7M · FY ending 2025-12-31
Graham numberiBenjamin Graham's ceiling for a cautious buyer: the highest share price his 1949 rule allows, at 15 times earnings and 1.5 times book value combined. A yardstick, not a forecast.
—
no number exists: EPS or book value is zero or negative
●Going-concern warningAuditor flagged substantial doubt about the company continuing for the next 12 months — a raise is usually required.
●Bankruptcy-risk zoneAltman Z-Score is in the distress zone (-9.74).
●Earnings-manipulation riskBeneish M-Score (27.69) is above the threshold — a screen for earnings-quality review, not an accusation (fast growers can trip it).
●Active dilution shelfAn effective S-3 shelf with 5 prospectus filing(s) in 12 months — shares may be getting sold into the market.
Educational tools — not financial advice. Fundamentals from SEC EDGAR (XBRL); prices are end-of-day (Databento). Scores are a transparent blend of the components shown, computed on our own data — a research aid, not a recommendation.